Earnings Releases·Nov 5, 2026, 6:31 AM ET

BD — Fiscal 2026 Earnings Summary

FY 2026 revenue grew 4.9% to $19.5 billion (3.9% FXN), while Adjusted Diluted EPS rose 6.7% to $12.70; Q4 2026 Adjusted EPS reached $4.15 (up 27.3% YoY) with operating income surging 92.5% to $1.0 billion.
FY 2027 guidance sets GAAP and FXN revenue growth at low single-digits, with Adjusted Diluted EPS projected between $13.10 and $13.30.
Strategic milestones include the completed spin-off of the Life Sciences business, a $19 billion U.S. manufacturing partnership with the federal government, and $2.4 billion in stock repurchases alongside $1.2 billion in dividends.
Balance sheet improvements saw long-term debt decline to $13.4 billion and free cash flow increase 42.5% to $2.9 billion, though the company recorded $450 million in non-cash asset impairment charges related to strategic exits.